A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Atavistik Bio, Inc
Eisai Inc.
Duke University
AstraZeneca
University Health Network, Toronto
Novartis
Brigham and Women's Hospital
AbbVie
Exelixis
Nuvectis Pharma, Inc.
pharmaand GmbH
University of Chicago
Tempus AI
N.N. Petrov National Medical Research Center of Oncology
Memorial Sloan Kettering Cancer Center
Checkpoint Therapeutics, Inc.
Karyopharm Therapeutics Inc
Carisma Therapeutics Inc
Revolution Medicines, Inc.
Salubris Biotherapeutics Inc
ENB Therapeutics, Inc